Introduction: Vietnam is a tropical and agricultural country. Annually, there are 30,000 cases of snake bite. Two venomous snake families cause the big medical problem. In this, Calloselasma rhodostoma (CR) is the most dangerous snake. Therefore, since 2001, the scientific research collaborations between Vietnam (VN) and Uiversity of Southern California (USC) were established. Since 2014 this project has been approved by VN government. The aims of the 1st project are to establish the technological process for purification of disintegrin from CR venom of VN (CRd.VN), to determin the molecular weigh, structure and its biological antitumor activities. Methods: The process of collection, lyophilization of CR venom from VN. Protein concentration of CR venom was determined by BCA assay. High Performance Liquid Chromatography (HPLC), SDS-PAGE, Mass spectrometry (MS)analysis and sequencing by tryptic digestion were used for purification of CRd.VN and its molecular weight (MW) and structure. Standard cell biology methods were employed to characterize CRd’s abilities (in vitro) to inhibit platelet aggregation, adhesion, migration and invasion of tumor cells. Its anti-cancer activity in a breast cancer (BC) murine model (in vivo ) was tested.The resuls: Peak No:7 of HPLC (CRd.VN), showed a single ≈10 kDa band on SDS-PAGE gel. CRd.VN’s MW, structure and the sequence are 7.33 kDa, a monomer containing 68 amino acids with an RGD motif (position 49-51) and 6 disulfide bonds. The anti-cancer activities of CRd.VN are very strong. Conclusion: We have shown that CRd.VN is a possible anti-tumor agent with clinical potential. However, further research is required on CRd.VN recombinant production, preliminary pharmacokinetics/ toxicology properties and anti-tumor activities.
Keyword: CRd anti-cancer.
(1):Vietnam Institute on Toxicology (VST).
(2):University of Medicine & Pharmacy of Haiphong.
(3):Biochemistry and Molecular Biology, Keck School of Medicine of USC.
A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA:
Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011.
(21) A. Bond, “Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus,” Proceedings
(Baylor University. Medical Center), vol. 19, no. 3, pp. 281–284, 2006.
(128) A. S. Kamiguti, M. Zuzel, and R. D. G. Theakston, “Snake venom metalloproteinases and
disintegrins: interactions with cells,” Brazilian Journal of Medical and Biological Research, vol.
, no. 7, pp. 853–862, 1998.
Brooks, P.C (1996). Role of integrins in angiogenesis. Europ.J.Cancer 32:2423-2429.
Chia-Hsin Yeh, Hui-Chin Peng, Rong- Seng Yang, and Tur-Fu Huang. Rhodostomin, A Snake Venom
Disintegrin, Inhibits Angiogenesis Elicited by Basic Fibroblast Growth Factor and Suppresses
Tumor Growth by A Selective αvβ3 Blockade of Endothelial Cells. Molecular Pharmacology.
: 1333-1342, 2001.
Radu (1) Contois, L., Akalu, A., Brooks, P.C., 2009. Integrins as “functional hubs” in the regulation of
pathological angiogenesis. Semin. Cancer Biol.
C. Tang, R. Yang, C. Liu, T. Huang, and W. Fu, “Differential susceptibility of osteosarcoma cells and
primary osteoblasts to cell detachment caused by snake venom metalloproteinase
protein,” Toxicon, vol. 43, no. 1, pp. 11–20, 2004.
Radu (8) Ellis, L.M., Reardon, D.A., 2009. Cancer: the nuances of therapy. Nature 458, 290–292
Golubkov,V., Hawes, D., Markland, Jr, F.S (2004). Angiogenic activity of contortrostatin, a disintegrin
from Agkistrodon contortrix contortrix snake venom. Angiogenesis in press.
Radu (3) Goodman, S.L., Holzemann, G., Sulyok, G.A., Kessler, H., 2002. Nanomolar small molecule
inhibitors for alpha v(beta)6, alpha v(beta)5, and
Alpha v(beta)3 integrins. J. Med. Chem. 45, 1045–1051.
Radu (2) Hood, J.D., Cheresh, D.A., 2002. Role of integrins in cell invasion and
migration. Nat. Rev. Cancer 2, 91–100.
H-Schiang, R-S Yang and T-F Huang, British Journal of Cancer, 1995: The Arg-Gly-Asp- containing
peptide, rhodostomin, inhibits in vitro cell adhesion to extracellular matrices and platelet
aggregation caused by Saos-2 human osteosarcoma cells.
Julian J.Calvete and R. David G. Theakston: Biochem. J. 2003: Snake venom disintegrins: novel
dimeric disintegrins and structural diversification by disulphide bond engineering.
Radu (5) Jurasz, P., Alonso-Escolano, D., Radomski, M.W., 2004. Platelet–cancer
interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br. J.
Pharmacol. 143, 819–826.
Kang, I.C., Lee, Y.D., Kim, D.S. (1999). A novel disintegrin salmosin inhibits tumor angiogenesis.
Cancer Res 59:3754-3760
Radu (6) Kim, S., Bell, K., Mousa, S.A., Varner, J.A., 2000a. Regulation of angiogenesis in vivo by
ligation of integrin alpha5beta1 with the central cell binding domain of fibronectin. Am. J. Pathol.
Radu (7) Kim, S., Harris, M., Varner, J.A., 2000b. Regulation of integrin alpha vbeta 3-mediated
endothelial cell migration and angiogenesis by integrin alpha5beta1 and protein kinase A. J.
Biol. Chem. 275, 33920–33928
(9) L. Brannon-Peppas and J. O. Blanchette, “Nanoparticles and systems, target for cancer
therapy,” Advanced Drug Delivery Reviews, vol. 64, pp. 206–212, 2012.
Leonardo A.Calderon, Andreimar M. Soares, BioMed Research Internationala, 2014: Review Article,
Antitumoral Activity of Snake Venom Proteins: New Trends in Cancer Therapy.
Lo-Chun Au and Kong-Bung Choo, Biochemical and Biophysical Research Communications, 1991: A
common precursor for a putative hemorrhagic protein and rhodostomin, a platelet aggregation
inhibitor of the venom of Calloselasma rhodostoma: Molecular cloning and sequence analysis.
M. Trikha, Y. A. de Clerck, and F. S. Markland, “Contortrostatin, a snake venom disintegrin, inhibits β1
integrin- mediated human metastatic melanoma cell adhesion and blocks experimental
metastasis,” Cancer Research, vol. 54, no. 18, pp. 4993–4998, 1994.
Mohit Trikha, Francis S. Markland, Cancer Research, 1994 : Contortrostatin, a Snake Venom
Disintegrin, Inhibits β1 Integrin –mediated Human Metastatic Melanoma Cell Adhesion and
Blocks Experimental Metastasis.
N. Hidetomo, J. R. David, G. L. D. David, et al., “Can anesthetic techniques or drugs affect cancer
recurrence in patients undergoing cancer surgery?”Journal of Anesthesia, vol. 27, no. 5, pp. 731–
(41) Radu Minea, Corey Helchowski, Barbara Rubino, Kyle Brodmann, Stephen Swenson , Francis
Markland, Jr. “ Development of a chimeric recombinant disintegrin as a cost-effective anticancer
agent with promising translational potential, Toxicon 59, pp 472-486, 2012.
Radu (4) Reardon, D.A., Nabors, L.B., Stupp, R., Mikkelsen, T., 2008. Cilengitide: an integrintargeting
arginine-glycine-aspartic acid peptide with promising activity for glioblastoma
multiforme. Expert Opin. Investig. Drugs 17, 1225–1235.
(149 (150) R. J. Gould, M. A. Polokoff, P. A. Friedman et al., “Disintegrins: a family of integrin
inhibitory proteins from viper venoms (43129B),” Proceedings of the Society for Experimental
Biology and Medicine, vol. 195, no. 2, pp. 168–171, 1990.
(10) S. Kamath and J. K. Buolamwini, “Targeting EGFR and HER-2 receptor tyrosine kinases for
cancer drug discovery and development,” Medicinal Research Reviews, vol. 26, no. 5, pp. 569–
Smith, P.K., Krohn, R.I., Hermanson, G.T., Mallia, A.K., Gartner, F.H., Provenzano, M.D., Fujimoto,
E.K. Olson,B.J., Klenk,D.C (1985). Measurement of protein using bicinchoninic acid. Anal.
S.A.Brooks, H. J. Lomax-Browne, T. M. Carter, C. E. Kinch, and D. M. S. Hall, “Molecular interactions
in cancer cell metastasis,” Acta Histochemica, vol. 112, no. 1, pp. 3–25, 2010.
(151) S. Niewiarowski, M. A. McLane, M. Kloczewiak, and G. J. Stewart, “Disintegrins and other
naturally occurring antagonists of platelet fibrinogen receptors,” Seminars in Hematology, vol.
, no. 4, pp. 289–300, 1994.
(42) S. Yang, M. Lu, C. Chien et al., “Induction of apoptosis in human leukemia K562 cells by
cardiotoxin III,” Life Sciences, vol. 76, no. 21, pp. 2513–2522, 2005.
Trikha,M., Rote, W.E., Manley, P.J., Lucchesi, B.R., Markland, F.S. (1994a) Purification and
chracterization of platelet aggregation inhibitors from snake venoms. Throb.Res. 73:39-52.
Trikha, M., Flores, M., Markland, F.S. (1994b). Disintegrns inhibit mammary carcinoma binding to
extracellular matrix protein. FASEB J 8: A873.
Trikha, M., De Clerck Y. A., Markland, F.S. (1994c). Contortrostatin, a snake venom disintegrin,
inhibits beta 1 integrin-mediated human metastatic melanoma cell adhesion and blocks
experimental metastasis. Cancer Res. 54:4993- 4998.
Vivek Kumar Vyas and Utsay Parmar, Asian Pac J Trop Biomed, 2013 : Therapeutic potential of snake
venom in cancer therapy : current perspectives.
(33) W. D. DeWys, H. C. Kwaan, and S. Bathina, “Effect of defibrination on tumor growth and
response to chemotherapy,” Cancer Research, vol. 36, no. 10, pp. 3584–3587, 1976.
Yeh, C.H., Peng, H.C., Huang, t.F. (1998). Accutin, a new disintegrin, inhibits angiogenesis in vitro
and in vivo by acting as integrin alphavbeta3 antagonist and inducing apoptosis. Blood 92:3268-
Yun Zhang. Why do we study animal toxins. Zoological research 36(4): 183-222, 2015.
Zhou,Q., Ritter, M., Markland, F.S. (1996). Contortrostatin, a snake venom protein, which is an
inhibitor of breast cancer progression. Mol.Biol. Cell 7 (Supp):425a
Zhou,Q., Nakada, M. T., Arnold, C., Markland, F.S. (1999). Contortrostatin, a dimeric disintegrin from
Agkistrodon contortrix contortrix, inhibits angiogenesis. Angiogenesis 3:259-269.